David Merrick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David Merrick has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Patrick Seale
University of Pennsylvania
6 shared publications Lan Cheng
Institute for Diabetes, Obesity & Metabolism Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 19104
2 shared publicationsRyan Calhoun
Institute of Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania
2 shared publicationsSarah Traynor
Institute for Diabetes, Obesity & Metabolism Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 19104
2 shared publications- Sarah Traynor
Institute of Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania
2 shared publications Ahab Alnemri
FM Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
1 shared publication
Latest Publications
- Open Access
SOX4 Reprograms Adipose Stromal Cells into a Cancer-Associated Fibroblast- like State to Drive Metabolic Disease
Pathogenic adipose tissue remodeling promotes metabolic disease in obesity, but the mechanisms that establish this unhealthy tissue state remain poorly understood. Here, we show that obesity drives SOX4-dependent reprogramming of mesenchymal stromal cells (MSCs) into cancer-associated fibroblast-like (CAF-like) cells that promote adipose tissue dysfunction. TGFβ signaling is elevated in obesity and activates SOX4 in mouse and human MSCs, inducing their conversion to a CAF-like state. In mice, MSC-specific SOX4 activation induces the CAF-like program and exacerbates adipose tissue inflammation and glucose intolerance, whereas Sox4 deletion attenuates inflammation and improves glucose homeostasis during obesity. We further identify the growth factor Midkine (MDK) as a SOX4-regulated paracrine effector produced by CAF-like cells. MDK inhibition in obese mice reduces adipose tissue inflammation and improves metabolic function. Together, these findings define a TGFβ-SOX4-MDK stromal signaling axis that drives pathological adipose tissue remodeling in obesity and highlight this pathway as a potential therapeutic target for improving metabolic health.
Open AccessSOX4 Reprograms Adipose Stromal Cells into a Cancer-Associated Fibroblast- like State to Drive Metabolic Disease
Pathogenic adipose tissue remodeling promotes metabolic disease in obesity, but the mechanisms that establish this unhealthy tissue state remain poorly understood. Here, we show that obesity drives SOX4-dependent reprogramming of mesenchymal stromal cells (MSCs) into cancer-associated fibroblast-like (CAF-like) cells that promote adipose tissue dysfunction. TGFβ signaling is elevated in obesity and activates SOX4 in mouse and human MSCs, inducing their conversion to a CAF-like state. In mice, MSC-specific SOX4 activation induces the CAF-like program and exacerbates adipose tissue inflammation and glucose intolerance, whereas Sox4 deletion attenuates inflammation and improves glucose homeostasis during obesity. We further identify the growth factor Midkine (MDK) as a SOX4-regulated paracrine effector produced by CAF-like cells. MDK inhibition in obese mice reduces adipose tissue inflammation and improves metabolic function. Together, these findings define a TGFβ-SOX4-MDK stromal signaling axis that drives pathological adipose tissue remodeling in obesity and highlight this pathway as a potential therapeutic target for improving metabolic health.
- Open Access
Glucokinase activity suppresses hepatic cholesterol synthesis and triglyceride accumulation: A new model for the effects of the GKRP P466L common human variant
Objective: Glucokinase Regulatory Protein (GKRP) controls the activity of Glucokinase (GCK) to regulate liver glucose uptake and storage. Coding variants in GCKR , the gene encoding GKRP, strongly associate with fatty liver disease, hypertriglyceridemia, and hypercholesterolemia. Here, we sought to investigate the mechanisms by which a common GKRP variant affects hepatic lipid and cholesterol metabolism. Methods: We developed mouse models to examine how the human GKRP P446L variant influences liver and systemic metabolism. Endogenous Gckr expression was ablated in adult mouse hepatocytes, together with re-expression of either human GKRP P446L or the reference GKRP protein. We assessed body weight, adiposity, systemic glucose homeostasis, and hepatic metabolites in mice expressing reference GKRP or GKRP P446L under multiple metabolic conditions. To determine whether the effects of GKRP P446L may result from reduced GCK activity, we analyzed mice with liver-specific deletion of Gck . Results: Hepatic expression of GKRP P446L resulted in reduced GKRP and GCK protein levels and elevated serum cholesterol. Hepatic deletion of Gck in mice recapitulated several effects of GKRP P446L, including increased hepatic cholesterol and triglyceride content. The elevated cholesterol was associated with increased cholesterogenic gene expression and cholesterol synthesis. Hepatic expression of an alternative hexokinase (HKII) normalized the effects of GCK-deficiency, suggesting that impaired glucose phosphorylation underlies the phenotype. Conclusions: The GKRP P446L variant reduced GKRP protein abundance, and diminished GCK activity while increasing cholesterol levels. Loss of GCK elevated cholesterol and hepatic triglyceride levels. Collectively, these findings demonstrate that GCK suppresses hepatic cholesterol synthesis and lipid accumulation, suggesting that reduced GCK activity underlies the metabolic abnormalities associated with the GKRP P446L variant. Highlights: The GKRP P446L variant reduces GKRP protein abundance and diminishes GCK activity. Expression of GKRP P446L in mouse hepatocytes increases serum cholesterol levels. GCK activity suppresses cholesterogenic gene expression and cholesterol synthesis.
Open AccessGlucokinase activity suppresses hepatic cholesterol synthesis and triglyceride accumulation: A new model for the effects of the GKRP P466L common human variant
Objective: Glucokinase Regulatory Protein (GKRP) controls the activity of Glucokinase (GCK) to regulate liver glucose uptake and storage. Coding variants in GCKR , the gene encoding GKRP, strongly associate with fatty liver disease, hypertriglyceridemia, and hypercholesterolemia. Here, we sought to investigate the mechanisms by which a common GKRP variant affects hepatic lipid and cholesterol metabolism. Methods: We developed mouse models to examine how the human GKRP P446L variant influences liver and systemic metabolism. Endogenous Gckr expression was ablated in adult mouse hepatocytes, together with re-expression of either human GKRP P446L or the reference GKRP protein. We assessed body weight, adiposity, systemic glucose homeostasis, and hepatic metabolites in mice expressing reference GKRP or GKRP P446L under multiple metabolic conditions. To determine whether the effects of GKRP P446L may result from reduced GCK activity, we analyzed mice with liver-specific deletion of Gck . Results: Hepatic expression of GKRP P446L resulted in reduced GKRP and GCK protein levels and elevated serum cholesterol. Hepatic deletion of Gck in mice recapitulated several effects of GKRP P446L, including increased hepatic cholesterol and triglyceride content. The elevated cholesterol was associated with increased cholesterogenic gene expression and cholesterol synthesis. Hepatic expression of an alternative hexokinase (HKII) normalized the effects of GCK-deficiency, suggesting that impaired glucose phosphorylation underlies the phenotype. Conclusions: The GKRP P446L variant reduced GKRP protein abundance, and diminished GCK activity while increasing cholesterol levels. Loss of GCK elevated cholesterol and hepatic triglyceride levels. Collectively, these findings demonstrate that GCK suppresses hepatic cholesterol synthesis and lipid accumulation, suggesting that reduced GCK activity underlies the metabolic abnormalities associated with the GKRP P446L variant. Highlights: The GKRP P446L variant reduces GKRP protein abundance and diminishes GCK activity. Expression of GKRP P446L in mouse hepatocytes increases serum cholesterol levels. GCK activity suppresses cholesterogenic gene expression and cholesterol synthesis.
- Open Access
- 3 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (1) , eads5963
Transcriptional regulation of adipocyte lipolysis by IRF2BP2
Adipocyte lipolysis controls systemic energy levels and metabolic homeostasis. Lipolysis is regulated by posttranslational modifications of key lipolytic enzymes. However, less is known about the transcriptional mechanisms that regulate lipolysis. Here, we identify interferon regulatory factor–2 binding protein 2 (IRF2BP2) as a transcriptional repressor of adipocyte lipolysis. Deletion of IRF2BP2 in human adipocytes increases lipolysis without affecting glucose uptake, whereas IRF2BP2 overexpression decreases lipolysis. RNA sequencing, and chromatin immunoprecipitation sequencing analyses show that IRF2BP2 represses lipolysis-related genes, including LIPE , which encodes hormone sensitive lipase, the rate-limiting enzyme in lipolysis. Adipocyte-selective deletion of Irf2bp2 in mice increases Lipe expression and free fatty acid levels, resulting in adipose tissue inflammation and glucose intolerance. Together, these findings demonstrate that IRF2BP2 restrains adipocyte lipolysis and opens avenues to target lipolysis for the treatment of metabolic disease.
- 3 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (1) , eads5963
Open AccessTranscriptional regulation of adipocyte lipolysis by IRF2BP2
Adipocyte lipolysis controls systemic energy levels and metabolic homeostasis. Lipolysis is regulated by posttranslational modifications of key lipolytic enzymes. However, less is known about the transcriptional mechanisms that regulate lipolysis. Here, we identify interferon regulatory factor–2 binding protein 2 (IRF2BP2) as a transcriptional repressor of adipocyte lipolysis. Deletion of IRF2BP2 in human adipocytes increases lipolysis without affecting glucose uptake, whereas IRF2BP2 overexpression decreases lipolysis. RNA sequencing, and chromatin immunoprecipitation sequencing analyses show that IRF2BP2 represses lipolysis-related genes, including LIPE , which encodes hormone sensitive lipase, the rate-limiting enzyme in lipolysis. Adipocyte-selective deletion of Irf2bp2 in mice increases Lipe expression and free fatty acid levels, resulting in adipose tissue inflammation and glucose intolerance. Together, these findings demonstrate that IRF2BP2 restrains adipocyte lipolysis and opens avenues to target lipolysis for the treatment of metabolic disease.
- Open Access
- 1 August 2024
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 38 (15-16) , 772-783
Developmental regulation of dermal adipose tissue by BCL11b
The distinct anatomic environment in which adipose tissues arise during organogenesis is a principle determinant of their adult expansion capacity. Metabolic disease results from a deficiency in hyperplastic adipose expansion within the dermal/subcutaneous depot; thus, understanding the embryonic origins of dermal adipose is imperative. Using single-cell transcriptomics throughout murine embryogenesis, we characterized cell populations, includingBcl11b+cells, that regulate the development of dermal white adipose tissue (dWAT). We discovered that BCL11b expression modulates the Wnt signaling microenvironment to enable adipogenic differentiation in the dermal compartment. Subcutaneous and visceral adipose arises from a distinct population ofNefl+cells during embryonic organogenesis, whereasPi16+/Dpp4+fibroadipogenic progenitors support obesity-stimulated hypertrophic expansion in the adult. Together, these results highlight the unique regulatory pathways used by anatomically distinct adipose depots, with important implications for human metabolic disease.
- 1 August 2024
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 38 (15-16) , 772-783
Open AccessDevelopmental regulation of dermal adipose tissue by BCL11b
The distinct anatomic environment in which adipose tissues arise during organogenesis is a principle determinant of their adult expansion capacity. Metabolic disease results from a deficiency in hyperplastic adipose expansion within the dermal/subcutaneous depot; thus, understanding the embryonic origins of dermal adipose is imperative. Using single-cell transcriptomics throughout murine embryogenesis, we characterized cell populations, includingBcl11b+cells, that regulate the development of dermal white adipose tissue (dWAT). We discovered that BCL11b expression modulates the Wnt signaling microenvironment to enable adipogenic differentiation in the dermal compartment. Subcutaneous and visceral adipose arises from a distinct population ofNefl+cells during embryonic organogenesis, whereasPi16+/Dpp4+fibroadipogenic progenitors support obesity-stimulated hypertrophic expansion in the adult. Together, these results highlight the unique regulatory pathways used by anatomically distinct adipose depots, with important implications for human metabolic disease.
- 3 October 2023
- Published by Elsevier in Cell Metabolism
- Vol. 35 (10) , 1679-1680
She didn’t start the fire: Mammary duct epithelial cells suppress adipocyte thermogenesis
- 3 October 2023
- Published by Elsevier in Cell Metabolism
- Vol. 35 (10) , 1679-1680
She didn’t start the fire: Mammary duct epithelial cells suppress adipocyte thermogenesis
- Open Access
- 14 June 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (11) , 110942
Inflammatory adipose activates a nutritional immunity pathway leading to retinal dysfunction
- 14 June 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (11) , 110942
Open AccessInflammatory adipose activates a nutritional immunity pathway leading to retinal dysfunction
- Open Access
- 15 October 2021
- Published by Elsevier in Molecular Metabolism
- Vol. 54, 101357
Dpp4+ interstitial progenitor cells contribute to basal and high fat diet-induced adipogenesis
- 15 October 2021
- Published by Elsevier in Molecular Metabolism
- Vol. 54, 101357
Open AccessDpp4+ interstitial progenitor cells contribute to basal and high fat diet-induced adipogenesis
- 1 June 2020
- Published by Elsevier in Cell Stem Cell
- Vol. 26 (6) , 801-803
Skinny Fat Cells Stimulate Wound Healing
- 1 June 2020
- Published by Elsevier in Cell Stem Cell
- Vol. 26 (6) , 801-803
Skinny Fat Cells Stimulate Wound Healing
- Top Cited Papers
- 26 April 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 364 (6438) , 353-+
Identification of a mesenchymal progenitor cell hierarchy in adipose tissue
A singular focus on fat: Fatty tissue can expand in two ways: through increases in the size of individual adipocytes or through increases in the number of adipocytes. The former process promotes metabolic disease, and the latter protects against it. Merrick et al. used single-cell RNA sequencing to define the hierarchy of mesenchymal progenitor cells that give rise to adipose tissue in mice and humans (see the Perspective by Chau and Cawthorn). They found that progenitor cells expressing a protein called DPP4 give rise to two distinct types of preadipocytes in response to different signals. The DPP4 progenitors reside in a fluid-filled network of collagen and elastin fibers surrounding adipose tissue. In principle, therapeutic interventions that increase progenitor cell differentiation into adipocytes could ameliorate metabolic disease. Science , this issue p. eaav2501 ; see also p. 328
- 26 April 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 364 (6438) , 353-+
Top Cited PapersIdentification of a mesenchymal progenitor cell hierarchy in adipose tissue
A singular focus on fat: Fatty tissue can expand in two ways: through increases in the size of individual adipocytes or through increases in the number of adipocytes. The former process promotes metabolic disease, and the latter protects against it. Merrick et al. used single-cell RNA sequencing to define the hierarchy of mesenchymal progenitor cells that give rise to adipose tissue in mice and humans (see the Perspective by Chau and Cawthorn). They found that progenitor cells expressing a protein called DPP4 give rise to two distinct types of preadipocytes in response to different signals. The DPP4 progenitors reside in a fluid-filled network of collagen and elastin fibers surrounding adipose tissue. In principle, therapeutic interventions that increase progenitor cell differentiation into adipocytes could ameliorate metabolic disease. Science , this issue p. eaav2501 ; see also p. 328
- Open Access
- 1 April 2019
- Published by Wiley in The FASEB Journal
- Vol. 33 (S1) , 863.10
Polycystin 1 is an atypical adhesion GPCR that responds to non‐canonical WNT signals and inhibits GSK3β
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in the PKD1 and PKD2 genes, which encode PC1 and PC2, respectively. PC1 is a 460kD multi‐spanning membrane protein. PC1 undergoes multiple proteolytic cleavages, one of which is an autocatalytic cleavage that produces a large N terminal fragment (NTF) that remains non‐covalently attached to the membrane‐embedded C terminal fragment (CTF). A recent study demonstrates that PC1 serves as a receptor for Wnt ligands through the direct binding of these ligands to the PC1 NTF. We find that PC1 responds to Wnt9b by shedding its 350kD NTF, which bears a striking resemblance to the activation mechanism of an adhesion GPCR. For aGPCRs, NTF removal liberates a short peptide sequence near the GPS cleavage site called stachel, which then interacts with an internal binding site and engages a G protein signalling cascade. We find that Wnt9b induces a PC1‐dependent phosphorylation and inhibition of the GSK3β kinase through the RhoA GTPase‐ROCK kinase pathway. Expression of a “constitutively active” aGPCR form of PC1 that lacks its NTF leads to profound suppression of GSK3β activity that is dependent upon RhoA and ROCK. Interestingly, GSK3β is an important negative regulator of the HIPPO/non‐canonical Wnt signaling target TAZ(WWTR1), lack of which leads to the development severe renal cysts. Furthermore, recent data show that pharmacological inhibition of GSK3β is beneficial in mouse models of ADPKD. We find that exogenous expression of an active form of TAZ in PC1 null cells or in PKD1a/b morphant zebrafish suppresses the development of relevant phenotypes. We also demonstrate that pharmacological inhibition of GSK3β leads to accumulation of the TAZ protein and to reduced cystogenesis in a 3D matrigel assay employing PC1 null cells. TAZ abundance and activity have been shown to be upregulated through the non‐canonical Wnt signalling pathway. We find that HEK293 cells that express PC1 and PC2 respond to Wnt9b treatment by significantly increasing TAZ abundance as compared to the wild type HEK293 cells treated in the same manner. Taken together, our data suggest that PC1 is an aGPCR‐like receptor for non‐canonical Wnt ligands that participates in a novel signalling pathway by linking non‐canonical Wnt ligands to the GSK3β‐dependent regulation of TAZ, a multifaceted signalling molecule whose absence is sufficient to induce renal cystic disease. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
- 1 April 2019
- Published by Wiley in The FASEB Journal
- Vol. 33 (S1) , 863.10
Open AccessPolycystin 1 is an atypical adhesion GPCR that responds to non‐canonical WNT signals and inhibits GSK3β
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in the PKD1 and PKD2 genes, which encode PC1 and PC2, respectively. PC1 is a 460kD multi‐spanning membrane protein. PC1 undergoes multiple proteolytic cleavages, one of which is an autocatalytic cleavage that produces a large N terminal fragment (NTF) that remains non‐covalently attached to the membrane‐embedded C terminal fragment (CTF). A recent study demonstrates that PC1 serves as a receptor for Wnt ligands through the direct binding of these ligands to the PC1 NTF. We find that PC1 responds to Wnt9b by shedding its 350kD NTF, which bears a striking resemblance to the activation mechanism of an adhesion GPCR. For aGPCRs, NTF removal liberates a short peptide sequence near the GPS cleavage site called stachel, which then interacts with an internal binding site and engages a G protein signalling cascade. We find that Wnt9b induces a PC1‐dependent phosphorylation and inhibition of the GSK3β kinase through the RhoA GTPase‐ROCK kinase pathway. Expression of a “constitutively active” aGPCR form of PC1 that lacks its NTF leads to profound suppression of GSK3β activity that is dependent upon RhoA and ROCK. Interestingly, GSK3β is an important negative regulator of the HIPPO/non‐canonical Wnt signaling target TAZ(WWTR1), lack of which leads to the development severe renal cysts. Furthermore, recent data show that pharmacological inhibition of GSK3β is beneficial in mouse models of ADPKD. We find that exogenous expression of an active form of TAZ in PC1 null cells or in PKD1a/b morphant zebrafish suppresses the development of relevant phenotypes. We also demonstrate that pharmacological inhibition of GSK3β leads to accumulation of the TAZ protein and to reduced cystogenesis in a 3D matrigel assay employing PC1 null cells. TAZ abundance and activity have been shown to be upregulated through the non‐canonical Wnt signalling pathway. We find that HEK293 cells that express PC1 and PC2 respond to Wnt9b treatment by significantly increasing TAZ abundance as compared to the wild type HEK293 cells treated in the same manner. Taken together, our data suggest that PC1 is an aGPCR‐like receptor for non‐canonical Wnt ligands that participates in a novel signalling pathway by linking non‐canonical Wnt ligands to the GSK3β‐dependent regulation of TAZ, a multifaceted signalling molecule whose absence is sufficient to induce renal cystic disease. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .